Skip to main content
Premium Trial:

Request an Annual Quote

Caliper s Q2 Revenues Up 7.5 Percent, Loss Narrows by More than Half

NEW YORK, July 28 (GenomeWeb News) - Caliper Life Sciences yesterday reported an uptick in revenues and narrowed losses for the second quarter of 2004.


Total revenues for the quarter were $20.3 million, up 7.5 percent from $18.9 million in the same period last year. Revenue from licensing fees and contracts almost doubled, to $4.3 million from $2.4 million during the year-ago quarter.


Research and development costs declined to $4.5 million, from $6.6 million during the year-ago quarter.


Caliper's net loss totaled $4.2 million, or $.14 per share, down from $9.5 million, or $.33 per share, in the second quarter of 2004.


As of June 30, Caliper had $5.1 million in cash and cash equivalents, and $35.7 million in marketable securities.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.